Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

View All Documentation

SAB4200592

Sigma-Aldrich

Anti-IDH1 antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody

Synonym(s):

Anti-IDH, Anti-IDP, Anti-PICD, Anti-isocitrate dehydrogenase 1 (NADP+), Anti-soluble

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

mouse, human

concentration

~1.0 mg/mL

technique(s)

immunoblotting: 1-2 μg/mL using extracts of mouse brain (S1 fraction).
immunoprecipitation (IP): 10 μg using lysates of HepG2 cells.
indirect immunofluorescence: 2-4 μg/mL using U-87 glioblastoma cells.

UniProt accession no.

O75874

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... IDH1(3417)

General description

Isocitrate dehydrogenase 1 (IDH1) is an isoform of IDH enzyme. It is a cytoplasmic NADP+-dependent enzyme, localized both in the cytoplasm and peroxisomes.

Immunogen

synthetic peptide corresponding to an internal sequence of human IDH1, conjugated to KLH. The corresponding sequence is highly conserved in mouse (single amino acid substitution) and highly conserved in rat IDH1 (89% sequence identity).

Biochem/physiol Actions

Isocitrate dehydrogenase (IDH) is a key metabolic enzyme that catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate (αKG) in the cytosol, by using either NAD+ or NADP+ as co-substrates. IDH1 appears to have a tumor suppressor activity and its inactivation leads to tumorigenesis partially mediated by induction of the HIF1 pathway. A genome-wide mutation study has shown that IDH1 is mutated in glioblastoma, acute myeloid leukemia (AML) and chondrosarcoma. Mutations in IDH1 specific to Arg132 (R132) impart the enzyme′s ability to generate 2- hydroxyglutarate (2HG) instead of αKG. Several IDH1 mutations have been identified in gliomas, including R132H, R132C, R132S, R132G and R132L, each may result in different tumor type with varied malignant progression.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation
Leonardi R, et al.
The Journal of Biological Chemistry, 287, 14615-14620 (2012)
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha
Zhao S, et al.
Science, 324, 261-265 (2009)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
Amary MF, et al.
The Journal of Pathology, 224, 334-343 (2011)
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky A, et al.
Current Opinion in Oncology, 24, 83-83 (2012)
Lenny Dang et al.
Nature, 462(7274), 739-744 (2009-11-26)
Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature of a major subset of primary human brain cancers. These mutations occur at a single amino acid residue of the IDH1 active site, resulting in loss of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service